Clinical Trials Browser

INDUSTRY × enfortumab vedotin × Clear all

NCT07475806 2026-04-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Recruiting

240 enrolled

Genitourinary

Muscle-invasive Bladder Cancer

NCT04960709 2026-04-14

VOLGA

Phase 3 Active not recruiting

712 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06011954 2026-04-14

A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

Recruiting

202 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Phase 2 Active not recruiting

329 enrolled 23 charts

BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT07232602 2026-04-13

MK-3475-04D

Phase 1/2 Recruiting

55 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07421700 2026-04-07

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Phase 1/2 Recruiting

132 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07484022 2026-04-07

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Phase 1 Recruiting

37 enrolled

Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT07287995 2026-04-01

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Phase 1/2 Recruiting

428 enrolled

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT03288545 2026-03-24

EV-103

Phase 1/2 Terminated

348 enrolled 2 FDA

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT05614739 2026-03-23

FORAGER-1

Phase 1 Recruiting

535 enrolled

Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 2 FDA

Genitourinary

Metastatic Urothelial Cancer

NCT06862219 2026-03-06

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Phase 4 Recruiting

100 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06483334 2026-02-18

MK-3475-04C

Phase 1/2 Active not recruiting

38 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

808 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

272 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06305767 2026-01-13

INTerpath-005

Phase 1/2 Active not recruiting

230 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Phase 3 Completed

608 enrolled 22 charts 2 FDA

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05014139 2025-11-20

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Terminated

37 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT04995419 2025-10-07

A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy

Phase 2 Completed

40 enrolled 34 charts

Genitourinary

Metastatic Urothelial Cancer

NCT07157956 2025-09-05

CVL006-T1002

Phase 1/2 Not yet recruiting

318 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03924895 2025-08-28

KEYNOTE-905

Phase 3 Active not recruiting

595 enrolled 3 FDA

Genitourinary

Urinary Bladder Neoplasms

NCT05524545 2025-07-25

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

Phase 1 Completed

36 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04223856 2025-06-13

EV-302

Phase 3 Active not recruiting

886 enrolled 12 charts 2 FDA

Genitourinary

Urothelial Cancer

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Phase 2/3 Recruiting

700 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05097599 2025-01-08

StrataPATH

Phase 2 Terminated

11 enrolled

Tumor-Agnostic

Neoplasms

NCT02091999 2024-11-01

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Phase 1 Completed

213 enrolled

GenitourinaryOther solid neoplasm

Metastatic Urothelial Cancer and Other Malignant Solid Tumors

NCT03070990 2024-10-18

A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 1 Completed

19 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT03219333 2024-08-27

EV-201

Phase 2 Completed

219 enrolled 32 charts 4 FDA

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT01409135 2024-03-12

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

Phase 1 Completed

34 enrolled

Tumor-Agnostic

Neoplasms

NCT03606174 2023-08-24

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Phase 2 Terminated

260 enrolled 28 charts

Genitourinary

Carcinoma, Transitional Cell

NCT04136808 2020-01-13

An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Approved for marketing

Genitourinary

Carcinoma, Transitional Cell